Spinal Muscular Atrophies

Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach

Volumn , Issue , 2015, Pages 117-145

  Darras, Basil T ^a,b   Markowitz, Jennifer A ^b   Monani, Umrao R ^c   De Vivo, Darryl C ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Department of Medicine   (United States)

^d NEUROLOGICAL INSTITUTE   (United States)

Author keywords

5q SMA; Dubowitz disease; Kugelberg Welander disease; Non 5q SMAs; Spinal muscular atrophy; Survival of motor neuron protein; Werdnig Hoffman disease

Indexed keywords

EID: 84929956868     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-417044-5.00008-1     Document Type: Chapter

References (223)

1. Werdnig G. Zwei fruihnfantile hereditare Falle von progressive Muskelatrophie unter dem Bilde der Dystrophie,aber auf neurotischer Grundlage. Arch Psychiatr Neurol 1891, 22:437-481.
2. Hoffmann J. Ueber chronische spinale Muskelatrophie im Kindesalter, auf familiärer Basis. Deutsch Z Nervenheilk 1893, 3:427-470.
3. Monani U.R., Lorson C.L., Parsons D.W., Prior T.W., Androphy E.J., Burghes A.H., et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 1999, 8:1177-1183.
4. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 1978, 15:409-413.
5. Ogino S., Leonard D.G., Rennert H., Ewens W.J., Wilson R.B. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet 2002, 110:301-307.
6. Ogino S., Wilson R.B., Gold B. New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet 2004, 12:1015-1023.
7. Sugarman E.A., Nagan N., Zhu H., Akmaev V.R., Zhou Z., Rohlfs E.M., et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet 2012, 20:27-32.
8. Mostacciuolo M.L., Danieli G.A., Trevisan C., Muller E., Angelini C. Epidemiology of spinal muscular atrophies in a sample of the Italian population. Neuroepidemiology 1992, 11:34-38.
9. Thieme A., Mitulla B., Schulze F., Spiegler A.W. Epidemiological data on Werdnig-Hoffmann disease in Germany (West-Thuringen). Hum Genet 1993, 91:295-297.
10. Mailman M.D., Heinz J.W., Papp A.C., Snyder P.J., Sedra M.S., Wirth B., et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 2002, 4:20-26.
11. Zaldivar T., Montejo Y., Acevedo A.M., Guerra R., Vargas J., Garofalo N., et al. Evidence of reduced frequency of spinal muscular atrophy type I in the Cuban population. Neurology 2005, 65:636-638.
12. Hendrickson B.C., Donohoe C., Akmaev V.R., Sugarman E.A., Labrousse P., Boguslavskiy L., et al. Differences in SMN1 allele frequencies among ethnic groups within North America. J Med Genet 2009, 46:641-644.
13. Prior T.W., Snyder P.J., Rink B.D., Pearl D.K., Pyatt R.E., Mihal D.C., et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A 2010, 152A:1608-1616.
14. Zerres K., Davies K.E. 59th ENMC International Workshop: Spinal Muscular Atrophies: recent progress and revised diagnostic criteria. 17-19 April 1998, Soestduinen, The Netherlands. Neuromuscul Disord 1999, 9:272-278.
15. Dubowitz V. Chaos in the classification of SMA: a possible resolution. Neuromuscul Disord 1995, 5:3-5.
16. Iannaccone S.T., Russman B.S., Browne R.H., Buncher C.R., White M., Samaha F.J. Prospective analysis of strength in spinal muscular atrophy. DCN/Spinal Muscular Atrophy Group. J Child Neurol 2000, 15:97-101.
17. Wang C.H., Finkel R.S., Bertini E.S., Schroth M., Simonds A., Wong B., et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 2007, 22:1027-1049.
18. Byers R.K., Banker B.Q. Infantile muscular atrophy. Arch Neurol 1961, 5:140-164.
19. Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol 1999, 3:49-51.
20. O'Hagen J.M., Glanzman A.M., McDermott M.P., Ryan P.A., Flickinger J., Quigley J., et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord 2007, 17:693-697.
21. Thomas N.H., Dubowitz V. The natural history of type I (severe) spinal muscular atrophy. Neuromuscul Disord 1994, 4:497-502.
22. Crawford T.O. Spinal muscular atrophies. Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach 2003, Butterworth Heinemann, Philadelphia, 145-66. H.R. Jones, D.C. De Vivo, B.T. Darras (Eds.).
23. Zerres K., Rudnik-Schöneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 1995, 52:518-523.
24. Munsat T., Davies K. Spinal muscular atrophy. 32nd ENMC International Workshop. Naarden, the Netherlands, 10-12 March 1995. Neuromuscul Disord 1996, 6:125-127.
25. Oskoui M., Levy G., Garland C.J., Gray J.M., O'Hagen J., De Vivo D.C., et al. The changing natural history of spinal muscular atrophy type 1. Neurology 2007, 69:1931-1936.
26. Menke L.A., Poll-The B.T., Clur S.A., Bilardo C.M., van der Wal A.C., Lemmink H.H., et al. Congenital heart defects in spinal muscular atrophy type I: a clinical report of two siblings and a review of the literature. Am J Med Genet A 2008, 146A:740-744.
27. Rudnik-Schöneborn S., Heller R., Berg C., Betzler C., Grimm T., Eggermann T., et al. Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J Med Genet 2008, 45:635-638.
28. Heier C.R., Satta R., Lutz C., DiDonato C.J. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum Mol Genet 2010, 19:3906-3918.
29. Bevan A.K., Hutchinson K.R., Foust K.D., Braun L., McGovern V.L., Schmelzer L., et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum Mol Genet 2010, 19:3895-3905.
30. Shababi M., Habibi J., Yang H.T., Vale S.M., Sewell W.A., Lorson C.L. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet 2010, 19:4059-4071.
31. Rudnik-Schöneborn S., Vogelgesang S., Armbrust S., et al. Digital necroses and vascular thrombosis in severe spinal muscular atrophy. Muscle Nerve 2010, 42:144-147.
32. Araujo Ade Q., Araujo M., Swoboda K.J. Vascular perfusion abnormalities in infants with spinal muscular atrophy. J Pediatr 2009, 155:292-294.
33. Rudnik-Schöneborn S., Goebel H.H., Schlote W., Graul-Neumann L., Fusch C., Zerres K. Classical infantile spinal muscular atrophy with SMN deficiency causes sensory neuronopathy. Neurology 2003, 60:983-987.
34. Thompson J., Bruce A. Progressive muscular atrophy in a child with a spinal lesion. Edinb Hosp Rep 1893, 1:372.
35. Dubowitz V. Infantile muscular atrophy: A prospective study with particular reference to a slowly progressive variety. Brain 1964, 87:707-718.
36. Sproule D.M., Montes J., Montgomery M., Battista V., Koenigsberger D., Shen W., et al. Increased fat mass and high incidence of overweight despite low body mass index in patients with spinal muscular atrophy. Neuromuscul Disord 2009, 19:391-396.
37. von Gontard A., Zerres K., Backes M., Laufersweiler-Plass C., Wendland C., Melchers P., et al. Intelligence and cognitive function in children and adolescents with spinal muscular atrophy. Neuromuscul Disord 2002, 12:130-136.
38. Zerres K., Rudnik-Schöneborn S., Forrest E., Lusakowska A., Borkowska J., Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci 1997, 146:67-72.
39. Kugelberg E., Welander L. Heredofamilial juvenile muscular atrophy simulating muscular dystrophy. AMA Arch Neurol Psychiatry 1956, 75:500-509.
40. MacLeod M.J., Taylor J.E., Lunt P.W., Mathew C.G., Robb S.A. Prenatal onset spinal muscular atrophy. Eur J Paediatr Neurol 1999, 3:65-72.
41. Bingham P.M., Shen N., Rennert H., Rorke L.B., Black A.W., Marin-Padilla M.M., et al. Arthrogryposis due to infantile neuronal degeneration associated with deletion of the SMNT gene. Neurology 1997, 49:848-851.
42. Korinthenberg R., Sauer M., Ketelsen U.P., Hanemann C.O., Stoll G., Graf M., et al. Congenital axonal neuropathy caused by deletions in the spinal muscular atrophy region. Ann Neurol 1997, 42:364-368.
43. Russman B.S. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol 2007, 22:946-951.
44. Guillot N., Cuisset J.M., Cuvellier J.C., Hurtevent J.F., Joriot S., Vallee L. Unusual clinical features in infantile Spinal Muscular Atrophies. Brain Dev 2008, 30:169-178.
45. Darras B.T. Non-5q spinal muscular atrophies: The alphanumeric soup thickens. Neurology 2011, 77:312-314.
46. Lefebvre S., Burglen L., Reboullet S., Clermont O., Burlet P., Viollet L., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155-165.
47. Lorson C.L., Androphy E.J. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 2000, 9:259-265.
48. Lefebvre S., Burlet P., Liu Q., Bertrandy S., Clermont O., Munnich A., et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997, 16:265-269.
49. Prior T.W. Spinal muscular atrophy diagnostics. J Child Neurol 2007, 22:952-956.
50. DiDonato C.J., Ingraham S.E., Mendell J.R., Prior T.W., Lenard S., Moxley R.T., et al. Deletions and conversion in spinal muscular atrophy patients: is there a relationship to severity?. Ann Neurol 1997, 41:230-237.
51. van der Steege G., Grootscholten P.M., Cobben J.M., Zappata S., Scheffer H., den Dunnen J.T., et al. Apparent gene conversions involving the SMN gene in the region of the spinal muscular atrophy locus on chromosome 5. Am J Hum Genet 1996, 59:834-838.
52. Campbell L., Potter A., Ignatius J., Dubowitz V., Davies K. Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype. Am J Hum Genet 1997, 61:40-50.
53. Feldkotter M., Schwarzer V., Wirth R., Wienker T.F., Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002, 70:358-368.
54. Arkblad E., Tulinius M., Kroksmark A.K., Henricsson M., Darin N. A population-based study of genotypic and phenotypic variability in children with spinal muscular atrophy. Acta Paediatr 2009, 98:865-872.
55. Saito M., Chen Y., Mizuguchi M., Igarashi T. [Quantitative analysis of SMN2 based on real-time PCR: correlation of clinical severity and SMN2 gene dosage]. No To Hattatsu 2005, 37:407-412.
56. Rudnik-Schöneborn S., Berg C., Zerres K., Betzler C., Grimm T., Eggermann T., et al. Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling. Clin Genet 2009, 76:168-178.
57. Prior T.W., Swoboda K.J., Scott H.D., Hejmanowski A.Q. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet A 2004, 130A:307-310.
58. Monani U.R., Sendtner M., Coovert D.D., Parsons D.W., Andreassi C., Le T.T., et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 2000, 9:333-339.
59. Hsieh-Li H.M., Chang J.G., Jong Y.J., Wu M.H., Wang N.M., Tsai C.H., et al. A mouse model for spinal muscular atrophy. Nat Genet 2000, 24:66-70.
60. Le T.T., Pham L.T., Butchbach M.E., Zhang H.L., Monani U.R., Coovert D.D., et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 2005, 14:845-857.
61. Prior T.W., Krainer A.R., Hua Y., Swoboda K.J., Snyder P.C., Bridgeman S.J., et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet 2009, 85:408-413.
62. Vezain M., Saugier-Veber P., Goina E., Touraine R., Manel V., Toutain A., et al. A rare SMN2 variant in a previously unrecognized composite splicing regulatory element induces exon 7 inclusion and reduces the clinical severity of spinal muscular atrophy. Hum Mutat 2010, 31:E1110-E1125.
63. Bernal S., Alias L., Barcelo M.J., Also-Rallo E., Martinez-Hernandez R., Gamez J., et al. The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor. J Med Genet 2010, 47:640-642.
64. Cobben J.M., van der Steege G., Grootscholten P., de Visser M., Scheffer H., Buys C.H. Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy. Am J Hum Genet 1995, 57:805-808.
65. Hahnen E., Forkert R., Marke C., Rudnik-Schoneborn S., Schonling J., Zerres K., et al. Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals. Hum Mol Genet 1995, 4:1927-1933.
66. Burghes A.H., Ingraham S.E., Kote-Jarai Z., Rosenfeld S., Herta N., Nadkarni N., et al. Linkage mapping of the spinal muscular atrophy gene. Hum Genet 1994, 93:305-312.
67. Oprea G.E., Krober S., McWhorter M.L., Rossoll W., Muller S., Krawczak M., et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 2008, 320:524-527.
68. Stratigopoulos G., Lanzano P., Deng L., Guo J., Kaufmann P., Darras B., et al. Association of plastin 3 expression with disease severity in spinal muscular atrophy only in postpubertal females. Arch Neurol 2010, 67:1252-1256.
69. Bernal S., Also-Rallo E., Martinez-Hernandez R., Alias L., Rodriguez-Alvarez F.J., Millan J.M., et al. Plastin 3 expression in discordant spinal muscular atrophy (SMA) siblings. Neuromuscul Disord 2011, 21:413-419.
70. Arnold W.D., Burghes A.H. Spinal muscular atrophy: development and implementation of potential treatments. Ann Neurol 2013, 74:348-362.
71. Bebee T.W., Gladman J.T., Chandler D.S. Splicing regulation of the survival motor neuron genes and implications for treatment of spinal muscular atrophy. Front Biosci (Landmark Ed) 2010, 15:1191-1204.
72. Sumner C.J., Kolb S.J., Harmison G.G., Jeffries N.O., Schadt K., Finkel R.S., et al. SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials. Neurology 2006, 66:1067-1073.
73. Prior TW, Russman BS, Spinal muscular atrophy. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle, 1993-2000. Feb 24 [updated 2013 Nov 14].
74. McAndrew P.E., Parsons D.W., Simard L.R., Rochette C., Ray P.N., Mendell J.R., et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet 1997, 60:1411-1422.
75. Eggermann T., Zerres K., Anhuf D., Kotzot D., Fauth C., Rudnik-Schöneborn S. Somatic mosaicism for a heterozygous deletion of the survival motor neuron (SMN1) gene. Eur J Hum Genet 2005, 13:309-313.
76. Smith M., Calabro V., Chong B., Gardiner N., Cowie S., du Sart D. Population screening and cascade testing for carriers of SMA. Eur J Hum Genet 2007, 15:759-766.
77. Swoboda K.J., Prior T.W., Scott C.B., McNaught T.P., Wride M.C., Reyna S.P., et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 2005, 57:704-712.
78. ACOG Committee opinion No.432 Spinal muscular atrophy. Obstet Gynecol 2009, 113:1194-1196.
79. Gitlin J.M., Fischbeck K., Crawford T.O., Cwik V., Fleischman A., Gonye K., et al. Carrier testing for spinal muscular atrophy. Genet Med 2010, 12:621-622.
80. Martínez-Hernández R., Soler-Botija C., Also E., Alias L., Caselles L., Gich I., et al. The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation. J Neuropathol Exp Neurol 2009, 68:474-481.
81. Liu Q., Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J 1996, 15:3555-3565.
82. Zhang H., Xing L., Rossoll W., Wichterle H., Singer R.H., Bassell G.J. Multiprotein complexes of the survival of motor neuron protein SMN with Gemins traffic to neuronal processes and growth cones of motor neurons. J Neurosci 2006, 26:8622-8632.
83. Meister G., Hannus S., Plottner O., Baars T., Hartmann E., Fakan S., et al. SMNrp is an essential pre-mRNA splicing factor required for the formation of the mature spliceosome. EMBO J 2001, 20:2304-2314.
84. Pellizzoni L., Yong J., Dreyfuss G. Essential role for the SMN complex in the specificity of snRNP assembly. Science 2002, 298:1775-1779.
85. Kolb S.J., Battle D.J., Dreyfuss G. Molecular functions of the SMN complex. J Child Neurol 2007, 22:990-994.
86. Pellizzoni L. Chaperoning ribonucleoprotein biogenesis in health and disease. EMBO Rep 2007, 8:340-345.
87. Cheng D., Cote J., Shaaban S., Bedford M.T. The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing. Mol Cell 2007, 25:71-83.
88. Rossoll W., Jablonka S., Andreassi C., Kroning A.K., Karle K., Monani U.R., et al. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J Cell Biol 2003, 163:801-812.
89. Beattie C.E., Carrel T.L., McWhorter M.L. Fishing for a mechanism: using zebrafish to understand spinal muscular atrophy. J Child Neurol 2007, 22:995-1003.
90. McWhorter M.L., Monani U.R., Burghes A.H., Beattie C.E. Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J Cell Biol 2003, 162:919-931.
91. Ruggiu M., McGovern V.L., Lotti F., Saieva L., Li D.K., Kariya S., et al. A role for SMN exon 7 splicing in the selective vulnerability of motor neurons in spinal muscular atrophy. Mol Cell Biol 2012, 32:126-138.
92. Lotti F., Imlach W.L., Saieva L., Beck E.S., Hao le T., Li D.K., et al. An SMN-dependent U12 splicing event essential for motor circuit function. Cell 2012, 151:440-454.
93. Imlach W.L., Beck E.S., Choi B.J., Lotti F., Pellizzoni L., McCabe B.D. SMN is required for sensory-motor circuit function in Drosophila. Cell 2012, 151:427-439.
94. Voigt T., Meyer K., Baum O., Schumperli D. Ultrastructural changes in diaphragm neuromuscular junctions in a severe mouse model for Spinal Muscular Atrophy and their prevention by bifunctional U7 snRNA correcting SMN2 splicing. Neuromuscul Disord 2010, 20:744-752.
95. 2+ homeostasis in nerve terminals of severe spinal muscular atrophy mice. J Neurosci 2010, 30:849-857.
96. Kong L., Wang X., Choe D.W., Polley M., Burnett B.G., Bosch-Marce M., et al. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J Neurosci 2009, 29:842-851.
97. Boon K.L., Xiao S., McWhorter M.L., Donn T., Wolf-Saxon E., Bohnsack M.T., et al. Zebrafish survival motor neuron mutants exhibit presynaptic neuromuscular junction defects. Hum Mol Genet 2009, 18:3615-3625.
98. Rossoll W., Bassell G.J. Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes. Results Probl Cell Differ 2009, 48:289-326.
99. Kariya S., Park G.H., Maeno-Hikichi Y., Leykekhman O., Lutz C., Arkovitz M.S., et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet 2008, 17:2552-2569.
100. Wadman R.I., Vrancken A.F., van den Berg L.H., van der Pol W.L. Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology 2012, 79:2050-2055.
101. Zerres K., Rudnik-Schöneborn S. 93rd ENMC International Workshop: non-5q-spinal muscular atrophies (SMA)-clinical picture (6-8 April 2001, Naarden, the Netherlands). Neuromuscul Disord 2003, 13:179-183.
102. Pestronk A. Hereditary motor syndromes 1996, Washington University, St. Louis, MO, [updated 21 Dec 2013; cited 27 Dec 2013]; Available from: .
103. Harms M.B., Allred P., Gardner R., Fernandes Filho J.A., Florence J., Pestronk A., et al. Dominant spinal muscular atrophy with lower extremity predominance: linkage to 14q32. Neurology 2010, 75:539-546.
104. Guenther U.P., Varon R., Schlicke M., Dutrannoy V., Volk A., Hubner C., et al. Clinical and mutational profile in spinal muscular atrophy with respiratory distress (SMARD): defining novel phenotypes through hierarchical cluster analysis. Hum Mutat 2007, 28:808-815.
105. Stalpers X.L., Verrips A., Poll-The B.T., Cobben J.M., Snoeck I.N., de Coo I.F., et al. Clinical and mutational characteristics of spinal muscular atrophy with respiratory distress type 1 in the Netherlands. Neuromuscul Disord 2013, 23:461-468.
106. Joseph S., Robb S.A., Mohammed S., Lillis S., Simonds A., Manzur A.Y., et al. Interfamilial phenotypic heterogeneity in SMARD1. Neuromuscul Disord 2009, 19:193-195.
107. Ciccolella M., Catteruccia M., Benedetti S., Moroni I., Uziel G., Pantaleoni C., et al. Brown-Vialetto-van Laere and Fazio-Londe overlap syndromes: a clinical, biochemical and genetic study. Neuromuscul Disord 2012, 22:1075-1082.
108. Namavar Y., Barth P.G., Poll-The B.T., Baas F. Classification, diagnosis and potential mechanisms in pontocerebellar hypoplasia. Orphanet J Rare Dis 2011, 6:50.
109. Renbaum P., Kellerman E., Jaron R., Geiger D., Segel R., Lee M., et al. Spinal muscular atrophy with pontocerebellar hypoplasia is caused by a mutation in the VRK1 gene. Am J Hum Genet 2009, 85:281-289.
110. Rudnik-Schöneborn S., Senderek J., Jen J.C., Houge G., Seeman P., Puchmajerova A., et al. Pontocerebellar hypoplasia type 1: clinical spectrum and relevance of EXOSC3 mutations. Neurology 2013, 80:438-446.
111. La Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991, 352:77-79.
112. Ramser J., Ahearn M.E., Lenski C., Yariz K.O., Hellebrand H., von Rhein M., et al. Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy. Am J Hum Genet 2008, 82:188-193.
113. Dlamini N., Josifova D.J., Paine S.M., Wraige E., Pitt M., Murphy A.J., et al. Clinical and neuropathological features of X-linked spinal muscular atrophy (SMAX2) associated with a novel mutation in the UBA1 gene. Neuromuscul Disord 2013, 23:391-398.
114. Washington University. Neuromuscular Disease Center [website]. 2014. Available from: <>. http://neuromuscular.wustl.edu.
115. Johns Hopkins University School of Medicine. McKusick-Nathans Institute of Genetic Medicine. Online Mendelian Inheritance in Man (OMIM). [website]. 2014. Available from: <>. http://www.ncbi.nlm.nih.gov/omim.
116. GeneTests [website]. 2014. Available from <>. http://www.genetests.org.
117. Neudorfer O., Pastores G.M., Zeng B.J., Gianutsos J., Zaroff C.M., Kolodny E.H. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med 2005, 7:119-123.
118. Johnson W.G. Motor neuron diseases resulting from hexosaminidase deficiency. Semin Neurol 1993, 13:369-374.
119. Jamrozik Z., Lugowska A., Golebiowski M., Krolicki L., Maczewska J., Kuzma-Kozakiewicz M. Late onset GM2 gangliosidosis mimicking spinal muscular atrophy. Gene 2013, 527:679-682.
120. Hirayama K., Toyokura Y., Tsubaki T. Juvenile muscular atrophy of unilateral upper extremity: a new clinical entity. Psychiatr Neurol Jpn 1959, 61:2190-2197.
121. Hirayama K. Juvenile non-progressive muscular atrophy localized in hand and forearm: observation in 38 cases. Clin Neurol (Tokyo) 1972, 12:313-324.
122. Kikuchi S., Tashiro K. Juvenile muscular atrophy of distal upper extremity (Hirayama's disease). Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach 2003, Butterworth-Heinemann, Philadelphia, 167-81. 1st ed. H.R.J. Jones, D.C. De Vivo, B.T. Darras (Eds.).
123. Hirayama K. Non-progressive juvenile spinal muscular atrophy of the distal upper limb (Hirayama's disease). Diseases of the Motor System; Handbook of Clinical Neurology 1991, Elsevier, Amsterdam, 107-20. P.J. Vinken, G.W. Bruyn, H.L. Klawans (Eds.).
124. Guo X.M., Qin X.Y., Huang C. Neuroelectrophysiological characteristics of Hirayama disease: report of 14 cases. Chin Med J (Engl) 2012, 125:2440-2443.
125. Ghosh P.S., Moodley M., Friedman N.R., Rothner A.D., Ghosh D. Hirayama disease in children from North America. J Child Neurol 2011, 26:1542-1547.
126. Kikuchi S., Tashiro K., Kitagawa M., Iwasaki Y., Abe H. [A mechanism of juvenile muscular atrophy localized in the hand and forearm (Hirayama's disease)-flexion myelopathy with tight dural canal in flexion]. Rinsho Shinkeigaku 1987, 27:412-419.
127. Iwasaki Y., Tashiro K., Kikuchi S., Kitagawa M., Isu T., Abe H. Cervical flexion myelopathy: a "tight dural canal mechanism." Case report. J Neurosurg 1987, 66:935-937.
128. Huang Y.L., Chen C.J. Hirayama disease. Neuroimaging Clin N Am 2011, 21:939-950. ix-x.
129. Hirayama K., Tomonaga M., Kitano K., Yamada T., Kojima S., Arai K. Focal cervical poliopathy causing juvenile muscular atrophy of distal upper extremity: a pathological study. J Neurol Neurosurg Psychiatry 1987, 50:285-290.
130. Hirayama K. Juvenile muscular atrophy of distal upper extremity (Hirayama disease): focal cervical ischemic poliomyelopathy. Neuropathology 2000, 20(Suppl):S91-S94.
131. Andreadou E, Christodoulou K, Manta P, Karandreas N, Loukaidis P, Sfagos C, et al. Familial asymmetric distal upper limb amyotrophy (Hirayama disease): report of a Greek family. Neurologist 2009, 15:156-160.
132. Paredes I., Esteban J., Ramos A., Gonzalez P., Rivas J.J. A severe case of Hirayama disease successfully treated by anterior cervical fusion. J Neurosurg Spine 2013, 20:191-195.
133. Agundez M., Rouco I., Barcena J., Mateos B., Barredo J., Zarranz J.J. Hirayama disease: Is surgery an option?. Neurologia 2013, doi:10.1016/j.nrl.2013.05.005.
134. Hosokawa T., Fujieda M., Wakiguchi H., Oosaki Y. Pediatric Hirayama disease. Pediatr Neurol 2010, 43:151-153.
135. Verma R, Lalla R, Patil TB, Gupta A. Hirayama disease: a frequently undiagnosed condition with simple inexpensive treatment. BMJ Case Rep 2012, 2012. ID: 23220833.
136. Monani U.R., De Vivo D.C. Neurodegeneration in spinal muscular atrophy: From disease phenotype and animal models to therapeutic strategies and beyond. Future Neurol 2014, 9:49-65.
137. Crawford T.O., Pardo C.A. The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis 1996, 3:97-110.
138. Simic G., Mladinov M., Seso Simic D., Jovanov Milosevic N., Islam A., Pajtak A., et al. Abnormal motoneuron migration, differentiation, and axon outgrowth in spinal muscular atrophy. Acta Neuropathol 2008, 115:313-326.
139. Dubowitz V. Muscle Disorders in Childhood 1995, Saunders, Philadelphia. 2nd ed.
140. Nadeau A., D'Anjou G., Debray G., Robitaille Y., Simard L.R., Vanasse M. A newborn with spinal muscular atrophy type 0 presenting with a clinicopathological picture suggestive of myotubular myopathy. J Child Neurol 2007, 22:1301-1304.
141. Martínez-Hernández R., Bernal S., Also-Rallo E., Alias L., Barcelo M.J., Hereu M., et al. Synaptic defects in type I spinal muscular atrophy in human development. J Pathol 2013, 229:49-61.
142. Schmid A., DiDonato C.J. Animal models of spinal muscular atrophy. J Child Neurol 2007, 22:1004-1012.
143. Park G.H., Maeno-Hikichi Y., Awano T., Landmesser L.T., Monani U.R. Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene. J Neurosci 2010, 30:12005-12019.
144. Ling K.K., Lin M.Y., Zingg B., Feng Z., Ko C.P. Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy. PLOS ONE 2010, 5:e15457.
145. Mentis G.Z., Blivis D., Liu W., Drobac E., Crowder M.E., Kong L. Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron 2011, 69:453-467.
146. Wishart T.M., Huang J.P., Murray L.M., Lamont D.J., Mutsaers C.A., Ross J., et al. SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum Mol Genet 2010, 19:4216-4228.
147. Mutsaers C.A., Wishart T.M., Lamont D.J., Riessland M., Schreml J., Comley L.H., et al. Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. Hum Mol Genet 2011, 20:4334-4344.
148. Martinez T.L., Kong L., Wang X., Osborne M.A., Crowder M.E., Van Meerbeke J.P., et al. Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy. J Neurosci 2012, 32:8703-8715.
149. Gogliotti R.G., Quinlan K.A., Barlow C.B., Heier C.R., Heckman C.J., Didonato C.J. Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. J Neurosci 2012, 32:3818-3829.
150. Lee A.J., Awano T., Park G.H., Monani U.R. Limited phenotypic effects of selectively augmenting the SMN protein in the neurons of a mouse model of severe spinal muscular atrophy. PLOS ONE 2012, 7:e46353.
151. Gavrilina T.O., McGovern V.L., Workman E., Crawford T.O., Gogliotti R.G., DiDonato C.J., et al. Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. Hum Mol Genet 2008, 17:1063-1075.
152. Le T.T., McGovern V.L., Alwine I.E., Wang X., Massoni-Laporte A., Rich M.M., et al. Temporal requirement for high SMN expression in SMA mice. Hum Mol Genet 2011, 20:3578-3591.
153. Lutz C.M., Kariya S., Patruni S., Osborne M.A., Liu D., Henderson C.E., et al. Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest 2011, 121:3029-3041.
154. Kariya S., Obis T., Garone C., Akay T., Sera F., Iwata S., et al. Requirement of enhanced survival motor neuron protein imposed during neuromuscular junction maturation. J Clin Invest 2014, 124:785-800.
155. Markowitz J.A., Singh P., Darras B.T. Spinal muscular atrophy: a clinical and research update. Pediatr Neurol 2012, 46:1-12.
156. Kaufmann P., McDermott M.P., Darras B.T., Finkel R., Kang P., Oskoui M., et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol 2011, 68:779-786.
157. Kaufmann P., McDermott M.P., Darras B.T., Finkel R.S., Sproule D.M., Kang P.B., et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 2012, 79:1889-1897.
158. Crawford T.O. Concerns about the design of clinical trials for spinal muscular atrophy. Neuromuscul Disord 2004, 14:456-460.
159. Montes J., McDermott M.P., Martens W.B., Dunaway S., Glanzman A.M., Riley S., et al. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology 2010, 74:833-838.
160. Glanzman A.M., Mazzone E., Main M., Pelliccioni M., Wood J., Swoboda K.J., et al. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord 2010, 20:155-161.
161. Nelson L., Owens H., Hynan L.S., Iannaccone S.T. The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy. Neuromuscul Disord 2006, 16:374-380.
162. Main M., Kairon H., Mercuri E., Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol 2003, 7:155-159.
163. Krosschell K.J., Maczulski J.A., Crawford T.O., Scott C., Swoboda K.J. A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord 2006, 16:417-426.
164. Montes J., Gordon A.M., Pandya S., De Vivo D.C., Kaufmann P. Clinical outcome measures in spinal muscular atrophy. J Child Neurol 2009, 24:968-978.
165. Kang P.B., Gooch C.L., McDermott M.P., Darras B.T., Finkel R.S., Yang M.L., et al. The motor neuron response to SMN1 deficiency in spinal muscular atrophy. Muscle Nerve 2014, 49:636-644.
166. Tsai L.K., Yang C.C., Ting C.H., Su Y.N., Hwu W.L., Li H. Correlation of survival motor neuron expression in leukocytes and spinal cord in spinal muscular atrophy. J Pediatr 2009, 154:303-305.
167. Tiziano F.D., Pinto A.M., Fiori S., Lomastro R., Messina S., Bruno C., et al. SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. Eur J Hum Genet 2010, 18:52-58.
168. Darras B.T., Kang P.B. Clinical trials in spinal muscular atrophy. Curr Opin Pediatr 2007, 19:675-679.
169. Singh P., Liew W.K., Darras B.T. Current advances in drug development in spinal muscular atrophy. Curr Opin Pediatr 2013, 25:682-688.
170. Lunke S., El-Osta A. The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy. J Neurochem 2009, 109:1557-1569.
171. Chang J.G., Hsieh-Li H.M., Jong Y.J., Wang N.M., Tsai C.H., Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001, 98:9808-9813.
172. Andreassi C., Angelozzi C., Tiziano F.D., Vitali T., De Vincenzi E., Boninsegna A., et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004, 12:59-65.
173. Brahe C., Vitali T., Tiziano F.D., Angelozzi C., Pinto A.M., Borgo F., et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 2005, 13:256-259.
174. Mercuri E., Bertini E., Messina S., Pelliccioni M., D'Amico A., Colitto F., et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 2004, 14:130-135.
175. Mercuri E., Bertini E., Messina S., Solari A., D'Amico A., Angelozzi C., et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007, 68:51-55.
176. Sumner C.J., Huynh T.N., Markowitz J.A., Perhac J.S., Hill B., Coovert D.D., et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003, 54:647-654.
177. Brichta L., Hofmann Y., Hahnen E., Siebzehnrubl F.A., Raschke H., Blumcke I., et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003, 12:2481-2489.
178. Swoboda K.J., Scott C.B., Reyna S.P., Prior T.W., LaSalle B., Sorenson S.L., et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLOS ONE 2009, 4:e5268.
179. Swoboda KJ, Scott CB, Crawford TO, Simard LR, Reyna SP, Krosschell KJ, et al. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLOS ONE 2010, 5:e12140.
180. Grzeschik S.M., Ganta M., Prior T.W., Heavlin W.D., Wang C.H. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 2005, 58:194-202.
181. Liang W.C., Yuo C.Y., Chang J.G., Chen Y.C., Chang Y.F., Wang H.Y., et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. J Neurol Sci 2008, 268:87-94.
182. Xu C., Chen X., Grzeschik S.M., Ganta M., Wang C.H. Hydroxyurea enhances SMN2 gene expression through nitric oxide release. Neurogenetics 2011, 12:19-24.
183. Chen T.H., Chang J.G., Yang Y.H., Mai H.H., Liang W.C., Wu Y.C., et al. Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. Neurology 2010, 75:2190-2197.
184. Kinali M., Mercuri E., Main M., De Biasia F., Karatza A., Higgins R., et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology 2002, 59:609-610.
185. Pane M., Staccioli S., Messina S., D'Amico A., Pelliccioni M., Mazzone E.S., et al. Daily salbutamol in young patients with SMA type II. Neuromuscul Disord 2008, 18:536-540.
186. Angelozzi C., Borgo F., Tiziano F.D., Martella A., Neri G., Brahe C. Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Med Genet 2008, 45:29-31.
187. Tiziano F.D., Lomastro R., Pinto A.M., Messina S., D'Amico A., Fiori S., et al. Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. J Med Genet 2010, 47:856-858.
188. Butchbach M.E., Singh J., Thorsteinsdottir M., Saieva L., Slominski E., Thurmond J., et al. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet 2010, 19:454-467.
189. Van Meerbeke J., Gibbs R., Plasterer H., Feng Z., Lin M., Wee C., et al. The therapeutic effects of RG3039 in severe spinal muscular atrophy mice and normal human volunteers [abstract]. Neurology 2012, 78(S25):003.
190. Garbes L., Riessland M., Holker I., Heller R., Hauke J., Trankle C., et al. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum Mol Genet 2009, 18:3645-3658.
191. Ting C.H., Lin C.W., Wen S.L., Hsieh-Li H.M., Li H. Stat5 constitutive activation rescues defects in spinal muscular atrophy. Hum Mol Genet 2007, 16:499-514.
192. Farooq F., Molina F.A., Hadwen J., MacKenzie D., Witherspoon L., Osmond M., et al. Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. J Clin Invest 2011, 121:3042-3050.
193. Biondi O., Branchu J., Sanchez G., Lancelin C., Deforges S., Lopes P., et al. In vivo NMDA receptor activation accelerates motor unit maturation, protects spinal motor neurons, and enhances SMN2 gene expression in severe spinal muscular atrophy mice. J Neurosci 2010, 30:11288-11299.
194. Wolstencroft E.C., Mattis V., Bajer A.A., Young P.J., Lorson C.L. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum Mol Genet 2005, 14:1199-1210.
195. Heier C.R., DiDonato C.J. Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. Hum Mol Genet 2009, 18:1310-1322.
196. Haddad H., Cifuentes-Diaz C., Miroglio A., Roblot N., Joshi V., Melki J. Riluzole attenuates spinal muscular atrophy disease progression in a mouse model. Muscle Nerve 2003, 28:432-437.
197. Russman B.S., Iannaccone S.T., Samaha F.J. A phase 1 trial of riluzole in spinal muscular atrophy. Arch Neurol 2003, 60:1601-1603.
198. Miller R.G., Moore D.H., Dronsky V., Bradley W., Barohn R., Bryan W., et al. A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 2001, 191:127-131.
199. Merlini L., Solari A., Vita G., Bertini E., Minetti C., Mongini T., et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol 2003, 18:537-541.
200. Lloyd A, Hunter N. Trophos completes patient enrollment in pivotal efficacy study of olesoxime in spinal muscular atrophy. Trophos; 2011 [updated 8 Sep 2011; cited Jan 4 2014]; Available from: <>. http://www.trophos.com/news/pr20110908.htm.
201. Burghes A.H., McGovern V.L. Antisense oligonucleotides and spinal muscular atrophy: skipping along. Genes Dev 2010, 24:1574-1579.
202. Hua Y., Vickers T.A., Okunola H.L., Bennett C.F., Krainer A.R. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 2008, 82:834-848.
203. Singh N.N., Shishimorova M., Cao L.C., Gangwani L., Singh R.N. A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol 2009, 6:341-350.
204. Hua Y., Sahashi K., Hung G., Rigo F., Passini M.A., Bennett C.F., et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010, 24:1634-1644.
205. Williams J.H., Schray R.C., Patterson C.A., Ayitey S.O., Tallent M.K., Lutz G.J. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J Neurosci 2009, 29:7633-7638.
206. Corti S., Nizzardo M., Nardini M., Donadoni C., Salani S., Ronchi D., et al. Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. Brain 2010, 133:465-481.
207. Ebert A.D., Yu J., Rose F.F., Mattis V.B., Lorson C.L., Thomson J.A., et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457:277-280.
208. Foust K.D., Wang X., McGovern V.L., Braun L., Bevan A.K., Haidet A.M., et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010, 28:271-274.
209. Passini M.A., Bu J., Roskelley E.M., Richards A.M., Sardi S.P., O'Riordan C.R., et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010, 120:1253-1264.
210. Valori C.F., Ning K., Wyles M., Mead R.J., Grierson A.J., Shaw P.J., et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2010, 2. 35ra42.
211. Dominguez E., Marais T., Chatauret N., Benkhelifa-Ziyyat S., Duque S., Ravassard P., et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 2011, 20:681-693.
212. Duque S., Joussemet B., Riviere C., Marais T., Dubreil L., Douar A.M., et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009, 17:1187-1196.
213. Gowing G., Svendsen C.N. Stem cell transplantation for motor neuron disease: current approaches and future perspectives. Neurotherapeutics 2011, 8:591-606.
214. Iannaccone S.T. Modern management of spinal muscular atrophy. J Child Neurol 2007, 22:974-978.
215. Schroth M.K. Special considerations in the respiratory management of spinal muscular atrophy. Pediatrics 2009, 123(Suppl. 4):S245-S249.
216. Mellies U., Dohna-Schwake C., Stehling F., Voit T. Sleep disordered breathing in spinal muscular atrophy. Neuromuscul Disord 2004, 14:797-803.
217. Markstrom A., Cohen G., Katz-Salamon M. The effect of long term ventilatory support on hemodynamics in children with spinal muscle atrophy (SMA) type II. Sleep Med 2010, 11:201-204.
218. Durkin E.T., Schroth M.K., Helin M., Shaaban A.F. Early laparoscopic fundoplication and gastrostomy in infants with spinal muscular atrophy type I. J Pediatr Surg 2008, 43:2031-2037.
219. Yuan N., Wang C.H., Trela A., Albanese C.T. Laparoscopic Nissen fundoplication during gastrostomy tube placement and noninvasive ventilation may improve survival in type I and severe type II spinal muscular atrophy. J Child Neurol 2007, 22:727-731.
220. Sproule D.M., Montes J., Dunaway S., Montgomery M., Battista V., Koenigsberger D., et al. Adiposity is increased among high-functioning, non-ambulatory patients with spinal muscular atrophy. Neuromuscul Disord 2010, 20:448-452.
221. Fujak A., Kopschina C., Forst R., Gras F., Mueller L.A., Forst J. Fractures in proximal spinal muscular atrophy. Arch Orthop Trauma Surg 2010, 130:775-780.
222. Montes J., Dunaway S., Montgomery M.J., Sproule D., Kaufmann P., De Vivo D.C., et al. Fatigue leads to gait changes in spinal muscular atrophy. Muscle Nerve 2011, 43:485-488.
223. Montes J., Blumenschine M., Dunaway S., Alter A.S., Engelstad K., Rao A.K., et al. Weakness and fatigue in diverse neuromuscular diseases. J Child Neurol 2013, 28:1277-1283.